Chu Grenoble

The trials here

What the 48 trials at this site are about, from their registry records.

Conditions

• Acute myeloid leukaemia6 trials
• Atrial fibrillation4 trials
• Childhood cancers4 trials
• Lung cancer4 trials
• Heart failure3 trials
• Schizophrenia3 trials
• Alzheimer disease2 trials
• Chronic lymphocytic leukaemia2 trials
• Cystic fibrosis2 trials
• High blood pressure2 trials
• Liver and biliary tract cancer2 trials
• Acute lymphoblastic leukaemia1 trial
• and 21 more

Phase

• Phase 210 trials
• Phase 33 trials
• Phase 2/31 trial

Status

• Recruiting16 trials
• Completed12 trials
• Not yet recruiting9 trials
• Active, not recruiting8 trials
• Terminated2 trials
• Enrolling by invitation1 trial

Lead sponsor

• Centre Hospitalier Universitaire de Saint Etienne4 trials
• Gustave Roussy, Cancer Campus, Grand Paris4 trials
• Assistance Publique - Hôpitaux de Paris3 trials
• UNICANCER3 trials
• University Hospital, Clermont-Ferrand3 trials
• and 22 more

Running trials

• Not yet recruiting

  Prognostic and Predictive Factors in Childhood Soft Tissue Sarcomas

  NCT07924384· Institut Curie· Source

  Contact: Séverine BOBILLIER-CHAUMONT, MD (principal investigator)

• Not yet recruiting

  Study Evaluating the Efficacy and Safety of the Addition of Ivosidenib to Oral Azacitidine (Onureg®) in Patients Over 55 With Acute Myeloid Leukemia (AML) and IDH1 Mutation, in Complete Remission After Intensive Chemotherapy.

  NCT07463768· Phase 2· French Innovative Leukemia Organisation· Source

  Contact: Martin CARRE

• Recruiting

  Validation of a Remediation Method for Memory Impairments Through Motor Encoding in Patients With Alzheimer's Disease

  NCT07632755· Centre Hospitalier Universitaire de Saint Etienne· Source

  Contact: Mathilde SAUVEE, MD (principal investigator)

• Recruiting

  Genotype/Phenotype Correlation of MORC2 Mutations

  NCT07038239· Hospices Civils de Lyon· Source

  Contact: Martial Mallaret, MD

• Recruiting

  Cohort of Patients With Chronic Myelomonocytic Leukemia

  NCT07512882· Gustave Roussy, Cancer Campus, Grand Paris· Source

  Contact: Sophie PARK

• Recruiting

  Early Identification of Patients Presenting a First Psychotic Episode, Non Answering to First Line Support Strategies

  NCT02670447· Centre Hospitalier Universitaire de Saint Etienne· Source

  Contact: Mircea POLOSAN, MD (principal investigator)

• Recruiting

  Oral Pooled Fecal Microbiotherapy (MaaT033) Concomitant to Cemiplimab Versus Best Investigator's Choice in Patients With Resistance to Treatment Due to Antibiotics Uptake With Advanced Non-small Cell Lung Cancer

  NCT07001618· Phase 2· Gustave Roussy, Cancer Campus, Grand Paris· Source

  Contact: Denis MOROS-SIBILOT, MD

• Enrolling by invitation

  the REMONO-CD and the REMONO-UC Studies

  NCT07564609· University Hospital, Clermont-Ferrand· Source

• Active, not recruiting

  A Registry on the FARAVIEW Technology of the OPAL HDx Mapping System When Used With the FARAWAVE NAV Ablation Catheter in the Treatment of Atrial Fibrillation

  NCT06808217· Boston Scientific Corporation· Source

• Recruiting

  Identification of Innovative Biomarkers to Predict Outcomes in Hepatocellular Carcinoma Treated With Tremelimumab and Durvalumab

  NCT06796114· Centre Hospitalier Universitaire de Besancon· Source

  Contact: Thomas DECAENS, Dr

• Recruiting

  Epidemiological Data on Mast Cell Pathologies in France

  NCT06186856· Imagine Institute· Source

  Contact: Laurence BOUILLET, Pr

• Recruiting

  Developmental and Epileptic Encephalopathy of Genetic Etiology: Natural History Through Reuse of Clinical Data

  NCT06380192· Imagine Institute· Source

  Contact: Fanny Dubois, Dr

• Recruiting

  CARE1 Pragmatic Clinical Trial

  NCT06364631· Phase 3· Gustave Roussy, Cancer Campus, Grand Paris· Source

  Contact: Mathieu LARAMAS, MD

• Recruiting

  The ME&MG Digital Solution for Autonomous Assessment of Myasthenia Gravis

  NCT05564936· Ad scientiam· Source

  Contact: Dr Lagrange

• Recruiting

  BradycArdia paCemaKer With AV Interval Modulation for Blood prEssure treAtmenT

  NCT06059638· Orchestra BioMed, Inc· Source

  Contact: Steven J. Evans, MD

• Recruiting

  Phase III Study Comparing GVHD Prophylaxis With ATG-thymoglobulin to ATLG-grafalon in Elderly Patients With Acute Myeloid Leukemia or Myelodysplasic Syndrome and Receiving an Allogeneic Hematopoietic Stem Cell Transplantation With a 10/10 HLA Matched Unrelated Donor

  NCT06083129· Phase 3· Assistance Publique - Hôpitaux de Paris· Source

  Contact: Claude-Eric Bulabois

• Recruiting

  SIOPEN BIOPORTAL, An International Registry Linked to a Virtual Biobank for Patients With Peripheral Neuroblastic Tumours

  NCT05192980· Institut Curie· Source

  Contact: Cécile PERRET, MD (principal investigator)

• Recruiting

  Study Comparing the Efficacy of 2 RIC Regimens (Clofarabine vs Fludarabine) in Adults With AML Eligible to Allo-SCT

  NCT05917405· Phase 2· Nantes University Hospital· Source

  Contact: Martin CARRE, Dr

• Recruiting

  Impact of an Early Identification Program for First-Episode Psychosis on the Duration of Untreated Psychosis

  NCT05813457· Centre Hospitalier Universitaire de Saint Etienne· Source

  Contact: Clément DONDE, MD (principal investigator)

• Recruiting

  Acute Myeloid Leukemia At Initial Diagnosis and/or Relapse in Children, Teenagers and Young Adults: Molecular Profiling, Multidrug Testing and MSC Interaction Studies

  NCT05772559· Assistance Publique - Hôpitaux de Paris· Source

  Contact: Corinne Armari Alla, MD

• Recruiting

  OPTImal Treatment of Sinus VENOSUS Defect

  NCT05865119· Centre Chirurgical Marie Lannelongue· Source

  Contact: Hélène BOUVAIST

• Recruiting

  EfFect of Ablation of Persistent AtriaL Fibrillation on COgNitive Function in Individuals With Mild Cognitive Impairment

  NCT05790707· Poitiers University Hospital· Source

  Contact: Peggy Jacon

• Active, not recruiting

  Real World Data Collection in Subjects Treated With the FARAPULSE Pulsed Field Ablation System

  NCT05501873· Boston Scientific Corporation· Source

• Recruiting

  Prognostic and Predictive Markers of Response to Treatment in Patients With Bile Duct Cancer: ACABi PRONOBIL Study

  NCT04935853· GERCOR - Multidisciplinary Oncology Cooperative Group· Source

  Contact: Gaël ROTH, MD

• Recruiting

  Venetoclax Resistance Landscape in Chronic Lymphocytic Leukemia

  NCT05246345· University Hospital, Clermont-Ferrand· Source

  Contact: Lise Laclautre

• Recruiting

  Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation With Post-transplant Cyclophosphamide in Patients With Acquired Refractory Aplastic Anemia or in Relapse After Immunosuppression

  NCT05126849· Phase 2· Assistance Publique - Hôpitaux de Paris· Source

  Contact: Claude-Eric Bulabois

• Recruiting

  Study Evaluating the Tailored Management of Locally-advanced Rectal Carcinoma

  NCT04749108· Phase 2/3· Institut du Cancer de Montpellier - Val d'Aurelle· Source

  Contact: Bertrand Trilling, MD (principal investigator)

• Active, not recruiting

  Assessment of the Axone Micro Quadripolar Lead for Enhanced Cardiac Resynchronization Therapy

  NCT04463641· MicroPort CRM· Source

• Active, not recruiting

  Microbial Biomarkers of EArly Pseudomonas Aeruginosa Colonization in CHildren With Cystic Fibrosis

  NCT03947957· University Hospital, Brest· Source

• Recruiting

  Securing Access to Innovative Molecules in Oncology and Hematology for Children, Adolescents and Young Adults

  NCT04477681· Gustave Roussy, Cancer Campus, Grand Paris· Source

  Contact: Dominique PLANTAZ, MD

• Active, not recruiting

  A Study of Cusatuzumab Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia Who Are Not Candidates for Intensive Chemotherapy

  NCT04023526· Phase 2· OncoVerity, Inc.· Source

• Active, not recruiting

  Preemptive Therapy for High Risk Chronic Lymphoid Leukemia Stage A

  NCT03766763· Phase 2· French Innovative Leukemia Organisation· Source

• Active, not recruiting

  Standard Treatment +/- SBRT in Solid Tumors Patients With Between 1 and 5 Bone-only Metastases

  NCT03143322· UNICANCER· Source

• Active, not recruiting

  Adjuvant Radiotherapy in Patients With Pathological High-risk Bladder Cancer (GETUG-AFU 30)

  NCT03333356· UNICANCER· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Acute myeloid leukaemia4 recruiting
• Childhood cancers4 recruiting
• Liver and biliary tract cancer2 recruiting
• Schizophrenia2 recruiting
• Alzheimer disease1 recruiting
• Aplastic anaemia1 recruiting
• Atrial fibrillation1 recruiting
• Charcot-Marie-Tooth disease1 recruiting
• Chronic lymphocytic leukaemia1 recruiting
• Chronic myeloid leukaemia1 recruiting
• Colorectal cancer1 recruiting
• Congenital heart disease1 recruiting
• Crohn's disease1 recruiting
• Epilepsy1 recruiting
• High blood pressure1 recruiting
• Kidney cancer1 recruiting
• Lung cancer1 recruiting
• Myasthenia gravis1 recruiting
• Neuroblastoma1 recruiting
• Sarcoma1 recruiting
• Ulcerative colitis1 recruiting

Closed trials

• Completed

  Phosphoproteomic Profile of Children With Down Syndrome

  NCT06279208· Perha Pharmaceuticals· Source

• Completed

  Validation of a Remediation Method for Memory Disorders Using Motor and Emotional Encoding in Patients With Alzheimer's Disease

  NCT06105047· Centre Hospitalier Universitaire de Saint Etienne· Source

• Completed

  DBLG1 System With TERUMO MEDISAFE WITH Insulin Pump Trial

  NCT05628532· Diabeloop· Source

• Completed

  Prevalence of Atrial Fibrillation in Cryptogenic Stroke With Patent Foramen Ovale Closure (PFO-AF) Study

  NCT04926142· Centre Hospitalier Universitaire de Besancon· Source

• Completed

  Safety and Performance of INVICTA Ventricular DF4 LEADS With Active Fixation-(APOLLO)

  NCT04590144· MicroPort CRM· Source

• Terminated

  Medico-economic Evaluation of Therapeutic Adaptation Guided by the Soluble Suppression of Tumorigenicity 2 (sST-2) Biomarker in the Management of Patients With Acute Heart Failure

  NCT04554277· University Hospital, Montpellier· Source

• Completed

  Study of Osimertinib in Patients with a Lung Cancer with Brain or Leptomeningeal Metastases with EGFR Mutation

  NCT04233021· Phase 2· Intergroupe Francophone de Cancerologie Thoracique· Source

• Completed

  Study of Ponatinib (Iclusig) for Prevention of Relapse After Allogeneic Stem Cell Transplantation (allo-SCT) in FLT3-ITD AML Patients

  NCT03690115· Phase 2· Versailles Hospital· Source

• Terminated

  Epidemiology and Clinical Characteristics of Non-Tuberculous Mycobacteria Infections in Cystic Fibrosis Patients.

  NCT03312075· University Hospital, Brest· Source

• Completed

  A Clinical Study to Investigate the Long-term Safety of the Drug Macitentan in Patients With Pulmonary Hypertension Who Were Previously Treated With Macitentan in Clinical Studies.

  NCT03422328· Phase 3· Actelion· Source

• Completed

  Evaluation of the Impact of Multiple Sclerosis and Its Treatments on Women Fertility

  NCT07164924· University Hospital, Clermont-Ferrand· Source

• Completed

  Study of Inotuzumab Ozogamicin Combined to Chemotherapy in Older Patients With Philadelphia Chromosome-negative CD22+ B-cell Precursor ALL

  NCT03249870· Phase 2· Versailles Hospital· Source

• Completed

  Explorations of the Normal Neural Behavioral and Pathological Bases of Metacognition

  NCT03140475· Versailles Hospital· Source

• Completed

  SAFIR02_Lung - Efficacy of Targeted Drugs Guided by Genomic Profiles in Metastatic NSCLC Patients

  NCT02117167· Phase 2· UNICANCER· Source